Last updated: February 15, 2026
Overview
NDC 00054-0237 corresponds to Otrexup (methotrexate) injection, marketed by Sandoz, used primarily for rheumatoid arthritis, psoriasis, and certain cancers. It is a subcutaneous formulation of methotrexate.
Market Size and Growth Dynamics
-
Historical Market Values (2020-2022): The global methotrexate market was valued at approximately $400 million in 2020, growing at an annual rate of 3%. The injection segment accounts for around 60% of this market, with Otrexup being a significant player due to its subcutaneous route offering improved bioavailability over oral formulations.
-
Key Competitors: Alternative methotrexate products include oral tablets and other injectable formulations like IM (intramuscular) methotrexate by Pfizer or Teva. The subcutaneous versions are gaining preference due to better absorption and tolerability.
-
Market Drivers: Increasing prevalence of rheumatoid arthritis and psoriasis, regulatory approvals for new indications, and physician preference for subcutaneous routes contribute to steady demand.
-
Challenges: Generic competition, patent expiry issues, and biosimilar entries may pressure prices and market share.
Pricing Trends and Projections
-
Current Price (Q2 2023): Wholesale acquisition cost (WAC) for a 10 mg/1 mL prefilled syringe is approximately $650. This is higher than oral methotrexate tablets (~$10-$30/month), owing to administration convenience and formulation costs.
-
Historical Price Trends: Since 2020, prices have increased by roughly 4-5% annually, aligned with inflation and increased demand.
-
Projected Price Trends (2023-2028): Price escalation is expected to slow to 2-3% annually due to market saturation and entry of biosimilars.
-
Potential Price Suppression Factors:
- Biosimilar approvals and market entry forecasted for 2024-2025.
- Payer negotiations and formulary placements pushing for lower prices.
- Increased availability of oral alternatives, which are less expensive.
Future Market and Price Estimates
| Year |
Estimated Average Wholesale Price (AWP) per 10 mg/1 mL syringe |
Notes |
| 2023 |
$650 |
Current pricing |
| 2024 |
$667 |
Slight increase expected |
| 2025 |
$684 |
Biosimilar competition emerges |
| 2026 |
$700 |
Market stabilizes; biosimilar expansion |
| 2027 |
$715 |
Price pressure from generics |
| 2028 |
$730 |
Broader generic/biosimilar adoption |
Regulatory and Policy Impacts
-
FDA Approvals: While no new formulations are pending approval, biosimilars are progressing, which could lead to price reductions.
-
Pricing Regulations: Policies on drug pricing and reimbursement, especially in Medicare and Medicaid, may impose price caps or rebate requirements.
Implications for Stakeholders
-
Manufacturers: Need to innovate or differentiate through dosing convenience, new indications, or combination therapies.
-
Payers: Focus on cost containment strategies, favoring oral generics or biosimilars.
-
Investors: Price trends suggest limited upside post-biosimilar introduction but stable demand in specialized markets.
Key Drivers and Risks
| Drivers |
Risks |
| Increasing disease prevalence |
Biosimilar market entry lowering prices |
| Physician preference for injectable formulations |
Regulatory delays for biosimilars |
| Improved formulation and administration options |
Patent disputes or exclusivity extensions |
Summary
Otrexup's market remains stable with moderate growth, supported by its advantageous route of administration. Price projections indicate modest increases until biosimilar competition becomes more established, likely leading to downward pressure from 2025 onward.
Key Takeaways
- The current wholesale price for NDC 00054-0237 is approximately $650 per syringe.
- The market is growing at about 3% annually, driven by disease prevalence.
- Price growth will slow in the coming years with biosimilar entry, expected around 2024–2025.
- Competition from generics and biosimilars will challenge revenue retention.
- Payers' negotiation power and policy shifts will influence future pricing dynamics.
FAQs
1. How does the price of Otrexup compare to other methotrexate formulations?
Otrexup's injectable form costs significantly more than oral pills, reflecting administration costs and formulation benefits. Oral methotrexate generally costs $10-$30 per month, whereas injectable forms like Otrexup cost around $650 per syringe.
2. When are biosimilars likely to impact the market?
Biosimilar methotrexate products are in late-stage development, with potential FDA approval by 2024–2025, which will likely reduce prices and market share for the originator.
3. What factors influence the pricing trajectory of injectable methotrexate?
Market competition, regulatory approvals, demand trends, payer negotiations, and manufacturing costs all affect pricing.
4. How might policy changes affect future prices?
Price caps, increased rebates, and formulary restrictions could reduce prices. Conversely, expanded indications or new formulations could support higher pricing.
5. What is the main driver for demand for NDC 00054-0237?
The main driver is the prevalence of autoimmune diseases like rheumatoid arthritis and psoriasis, which require methotrexate as a standard treatment.
References
- IQVIA. "Pharmaceutical Market Outlook 2022."
- FDA. "Biosimilar Product Development & Approval."
- CMS. "Medicare Part B Drug Spending & Reimbursement Data."
- Sandoz. "Otrexup Prescribing Information."
- MarketWatch. "Global Rheumatoid Arthritis Market Analysis," 2023.
